Subscribe
istock-855160904casarsaguru
CasarsaGuru / iStockphoto.com
30 July 2018Biotechnology

CJEU gene-editing decision ‘could stifle’ innovation in Europe

A ruling handed down last week by the Court of Justice of the European Union (CJEU) could stifle innovation in the gene-editing field, causing Europe to lag behind the rest of the world, commentators say.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.

More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB